🏛️ Verified NIH Record • Updated 2025-09-12
SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial (NCT03306680)
🔵 Active, Not Recruiting Phase1 📋 Clinical Research Protocol Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
🩺 Plain-English Summary (8th-Grade Level)
This multi-centre phase I dose-escalation study will use a time-to-event continual reassessment method (TIT-CRM). Accrual will start at level 1 (60 Gy in 8 fractions). Patients will be assigned to treatment doses using the TITE-CRM model. The model will use all available information from previously accrued patients to assign the highest dose with a predicted risk of grade 3 toxicity of 30% or less.
Who can join: Review the eligibility criteria below.
Location: BC Cancer -Vancouver Island — Vancouver, British Columbia
Age range: 18 Years
🧪 Interventions in This Study
- SBRT (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- BC Cancer -Vancouver Island — Vancouver, British Columbia
- London Regional Cancer Program — London, Ontario
- Sunnybrook Odette Cancer Centre — Toronto, Ontario
- Princess Margaret Cancer Centre — Toronto, Ontario
- Centre Hospitalier de l'Universite de Montreal (CHUM) — Montreal, Quebec
- McGill University Health Centre-Cedars Cancer Centre — Montreal, Quebec
- Saskatoon Cancer Centre — Saskatoon, Saskatchewan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non Small Cell Lung Cancer
- The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance — Boston, Massachusetts
- A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer — Middletown, New Jersey
- Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC — Beverly Hills, California
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer — Columbus, Georgia
- Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease — Edmonton, Alberta
- A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer — Springdale, Arkansas
Explore by condition: All Non Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.